With the deal, announced Nov. 24, Novartis gains Medicine Co.’s cholesterol-lowering drug Inclisiran, which uses a new technique called RNA interference to help especially hard-to-treat patients.
If FDA-approved, Inclisiran is predicted to reach peak annual sales of $4 billion, according to Bloomberg.
“We’re hoping to reimagine treatment of the leading global cause of death,” Novartis CEO Vas Narasimhan tweeted Nov. 24. ” This could be a strong step forward in Novartis’ transformation into a focused medicines company.”
Shares of Medicines Co. were up by 23 percent in trading before U.S. exchanges opened Nov. 25.
Read the full article here.
More articles on pharmacy:
AHA, CVS Health backed secretive anti-pharma group
EpiPen, Humira among drugs Warren wants to regulate
31 drugmakers at high risk for bankruptcy in 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
